CA2074370C - Antigenes synthetiques pour le depistage d'anticorps du virus de l'hepatite c - Google Patents

Antigenes synthetiques pour le depistage d'anticorps du virus de l'hepatite c Download PDF

Info

Publication number: CA2074370C
Authority: CA; Canada
Prior art keywords: pro; arg; glu; gln; lys
Prior art date: 1990-12-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2074370A

Other languages

English (en)

Other versions

CA2074370A1 (fr

Inventor

Robert J. Deleys

Dirk Pollet

Geert Maertens

Hugo Van Heuverswijn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fujirebio Europe NV SA

Original Assignee

Innogenetics NV SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-12-14

Filing date

1991-12-13

Publication date

2011-02-15

1990-12-14 Priority claimed from SG1996005024A external-priority patent/SG47062A1/en

1991-12-13 Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA

1992-06-15 Publication of CA2074370A1 publication Critical patent/CA2074370A1/fr

2011-02-15 Application granted granted Critical

2011-02-15 Publication of CA2074370C publication Critical patent/CA2074370C/fr

2011-12-13 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000001514 detection method Methods 0.000 title claims abstract description 34
241000711549 Hepacivirus C Species 0.000 title claims description 79
108010008038 Synthetic Vaccines Proteins 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 527
150000001413 amino acids Chemical class 0.000 claims abstract description 315
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 197
235000001014 amino acid Nutrition 0.000 claims description 187
239000000203 mixture Substances 0.000 claims description 71
239000007790 solid phase Substances 0.000 claims description 58
238000000034 method Methods 0.000 claims description 37
230000001900 immune effect Effects 0.000 claims description 35
230000008878 coupling Effects 0.000 claims description 30
238000010168 coupling process Methods 0.000 claims description 30
238000005859 coupling reaction Methods 0.000 claims description 30
210000001124 body fluid Anatomy 0.000 claims description 21
239000010839 body fluid Substances 0.000 claims description 21
239000004677 Nylon Substances 0.000 claims description 19
229920001778 nylon Polymers 0.000 claims description 19
239000012528 membrane Substances 0.000 claims description 18
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
239000012634 fragment Substances 0.000 claims description 16
235000018977 lysine Nutrition 0.000 claims description 16
230000008569 process Effects 0.000 claims description 15
241000700605 Viruses Species 0.000 claims description 12
235000018417 cysteine Nutrition 0.000 claims description 12
239000007787 solid Substances 0.000 claims description 12
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 11
210000002966 serum Anatomy 0.000 claims description 11
238000006467 substitution reaction Methods 0.000 claims description 11
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 10
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 10
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims description 10
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 9
239000004472 Lysine Substances 0.000 claims description 9
235000003704 aspartic acid Nutrition 0.000 claims description 9
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
235000013922 glutamic acid Nutrition 0.000 claims description 9
239000004220 glutamic acid Substances 0.000 claims description 9
238000010348 incorporation Methods 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
235000002374 tyrosine Nutrition 0.000 claims description 9
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 9
238000003018 immunoassay Methods 0.000 claims description 8
150000002669 lysines Chemical class 0.000 claims description 7
208000005176 Hepatitis C Diseases 0.000 claims description 6
229960002685 biotin Drugs 0.000 claims description 5
235000020958 biotin Nutrition 0.000 claims description 5
239000011616 biotin Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
238000001179 sorption measurement Methods 0.000 claims description 5
230000002194 synthesizing effect Effects 0.000 claims description 5
229960005486 vaccine Drugs 0.000 claims description 5
238000000338 in vitro Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000005647 linker group Chemical group 0.000 claims 35
125000004122 cyclic group Chemical group 0.000 claims 5
210000004899 c-terminal region Anatomy 0.000 claims 2
102000004169 proteins and genes Human genes 0.000 abstract description 8
108090000623 proteins and genes Proteins 0.000 abstract description 8
239000000427 antigen Substances 0.000 abstract description 7
108091007433 antigens Proteins 0.000 abstract description 7
102000036639 antigens Human genes 0.000 abstract description 7
238000003556 assay Methods 0.000 abstract description 5
239000003153 chemical reaction reagent Substances 0.000 abstract description 2
239000010836 blood and blood product Substances 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
238000009739 binding Methods 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
230000003287 optical effect Effects 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
238000012360 testing method Methods 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
230000001684 chronic effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000012286 ELISA Assay Methods 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000002131 composite material Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
108010076039 Polyproteins Proteins 0.000 description 3
101710172711 Structural protein Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
125000003636 chemical group Chemical group 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000004033 plastic Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 2
-1 2,2,5,7,8-pentamethylchroman-6-sulfonyl moiety Chemical group 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
241000710831 Flavivirus Species 0.000 description 2
206010019791 Hepatitis post transfusion Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
239000011324 bead Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
PRIQPGUUEABMCC-UHFFFAOYSA-N 2-[4-[1-amino-1-(2,4-dimethoxyphenyl)-2-(9h-fluoren-9-ylmethoxy)-2-oxoethyl]phenoxy]acetic acid Chemical compound COC1=CC(OC)=CC=C1C(N)(C=1C=CC(OCC(O)=O)=CC=1)C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 PRIQPGUUEABMCC-UHFFFAOYSA-N 0.000 description 1
RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 1
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
101800001386 Peptide II Proteins 0.000 description 1
101800005164 Peptide V Proteins 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
206010040102 Seroma Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241001147693 Staphylococcus sp. Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
108700010756 Viral Polyproteins Proteins 0.000 description 1
108700022715 Viral Proteases Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
230000008850 allosteric inhibition Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000005465 channeling Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012258 culturing Methods 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
229960004132 diethyl ether Drugs 0.000 description 1
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
239000012224 working solution Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)

CA2074370A 1990-12-14 1991-12-13 Antigenes synthetiques pour le depistage d'anticorps du virus de l'hepatite c Expired - Lifetime CA2074370C (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SG1996005024A SG47062A1 (en)	1990-12-14	1990-12-14	Synthetic antigens for the detection of antibodies to hepatitis virus
EP90124241.2		1990-12-14
EP90124241A EP0489968B1 (fr)	1990-12-14	1990-12-14	Antigènes synthétiques pour la détection des anticorps contre le virus de l'hépatite C
PCT/EP1991/002409 WO1992010514A2 (fr)	1990-12-14	1991-12-13	Antigenes synthetiques pour la detection d'anticorps diriges contre le virus de l'hepatite c

Publications (2)

Publication Number	Publication Date
CA2074370A1 CA2074370A1 (fr)	1992-06-15
CA2074370C true CA2074370C (fr)	2011-02-15

Family

ID=43606393

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2074370A Expired - Lifetime CA2074370C (fr)	1990-12-14	1991-12-13	Antigenes synthetiques pour le depistage d'anticorps du virus de l'hepatite c

Country Status (1)

Country	Link
CA (1)	CA2074370C (fr)

1991
- 1991-12-13 CA CA2074370A patent/CA2074370C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2074370A1 (fr)	1992-06-15

Legal Events

Date	Code	Title	Description
1993-01-27	EEER	Examination request
2011-12-13	MKEX	Expiry

Publication	Publication Date	Title
EP0644202B1 (fr)	1997-03-05	Antigènes synthétiques pour la détection des anticorps contre le virus de l'hépatite C
EP0589004B1 (fr)	1999-05-06	Procede de determination de peptides correspondant a des epitopes hcv importants d'un point de vue immunologique
DE69132365T2 (de)	2001-04-05	Für den Nachweis von Antikörpern gegen HVC spezifische synthetische Peptide und Diagnose von HCV-Infektionen
US20120270208A1 (en)	2012-10-25	Synthetic antigens for the detection of antibodies to hepatitis c virus
IE910928A1 (en)	1991-10-09	Peptides immunochemically reactive with antibodies directed¹against hepatitis non-a, non-b virus
US5582968A (en)	1996-12-10	Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5639594A (en)	1997-06-17	Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
AU655112B2 (en)	1994-12-01	HCV peptide antigens and method of determining HCV
HK57497A (en)	1997-05-09	Synthetic antigens for the detection of antibodies to hepatitis C virus
AU640569B2 (en)	1993-08-26	Assay for non-a non-b hepatitis
AU3572593A (en)	1993-09-13	Hepatitis C virus peptides
DE69033316T2 (de)	2000-05-11	Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C Virus
JPH04221398A (ja)	1992-08-11	非ａ非ｂ型肝炎ウイルスに対する抗体と免疫化学反応するペプチド